Neurodon is a biopharmaceutical company with small molecules in IND-enabling studies for type 1 and type 2 diabetes and Alzheimer's disease.
Neurodon has raised $2.9M in total funding. The most recent round was Grant. The last funding was announced in October 2023.
Neurodon's investors include Breakthrough T1D, National Institutes of Health.
Neurodon is headquartered in Crown Point, United States.
Neurodon is a biopharmaceutical company with small molecules in IND-enabling studies for type 1 and type 2 diabetes and Alzheimer's disease.
Neurodon is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Neurodon — Funding & Investors." VCBacked, October 3, 2023, https://www.vcbacked.co/company/neurodon. Accessed August 13, 2026.
VCBacked. (2023). Neurodon — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/neurodon
{{cite web |title=Neurodon — Funding & Investors |url=https://www.vcbacked.co/company/neurodon |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated